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ABSTRACT
The pathological changes in chronic bronchitis (CB) produce airﬂow obstruction, reduce the
effectiveness of the mucocilliary drainage system and lead to bacterial colonisation of bronchial
secretion. The presence of bacteria induces an inﬂammatory response mediated by leukocytes. There is a
direct relationship between the degree of impairment of the mucocilliary drainage system, the density of
bacteria in mucus and the number of leukocytes in the sputum. Purulent sputum is a good marker of a
high bacterial load. Eventually, if the number of leukocytes is high, their normal activity could decrease
the effectiveness of the drainage system, increase the bronchial obstruction and probably damage the
lung parenchyma.Whenever the density of bacteria in the bronchial lumen is ‡ 106 CFU ⁄mL, there is a
high probability that the degree of inﬂammatory response will lead to a vicious cycle which in turn
tends to sustain the process. This situation can arise during the clinical course of any acute exacerbation
of CB, independently of its aetiology, provided the episode is sufﬁciently severe and ⁄ or prolonged.
Fluoroquinolones of the third and fourth generation are bactericidal against most microorganisms
usually related to acute exacerbations of CB. Their diffusion to bronchial mucus is adequate. When used
in short (5-day) treatment they reduce the bacterial load in a higher proportion than is achieved by b-
lactam or macrolide antibiotics given orally. Although the clinical cure rate is similar to that obtained
with other antibiotics, the time between exacerbations could be increased.
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INTRODUCTION
Chronic bronchitis (CB) is clinically deﬁned as the
presence of productive cough lasting more than
three consecutive months over two consecutive
years [1]. Patients with a clinical diagnosis of CB
suffer from several changes in the respiratory
tract. The airway changes, mostly located in
bronchioles, include different degrees of: chronic
inﬂammatory inﬁltration of the mucosa, mainly
due to macrophages and T lymphocytes (CD8);
reduction of the number of ciliated cells, as well
as of the ciliary length; an hypertrophy of bron-
chial submucosa glands, as well as of caliciform
cells, which in turn leads to an excess of mucus
production; and progressive ﬁbrosis of the airway
wall, including loss of the elastic ﬁbres that keep
bronchioles open [2–5].
The above changes are due to the primary and
secondary immunological response to the long-
term inhalation of smoke, harmful gases or
biological dust [6]. In developed countries, tobac-
co smoke is responsible for more than 90% of
cases of CB. However, only 15% of heavy smok-
ers will develop a CB. In nearly 20% of them, the
disease will not progress. This fact suggests that a
particular baseline genetic individual susceptibil-
ity is necessary, as shown by the presence of
several polymorphisms in genes that codify for
inﬂammatory mediators, proteases or antiproteas-
es [7,8], by the development of an autoimmune
response [9] or perhaps by the presence of chronic
viral infection [10–12] or an infection due to
Chlamydophila pneumoniae [13]. The structural and
functional changes that develop in patients with
CB will lead to nonreversible and slowly progres-
sive obstruction of the bronchial lumen, as well as
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to a reduction of the effectiveness of the mucoc-
illiary drainage system[14].
Microorganisms that eventually enter respirat-
ory airways, via inhaled air or following micro-
aspiration of the pharyngeal contents, impact
with the mucus of the airways, and then are
trapped by mucin macromolecules. Next, the
mucocilliary drainage system carries these micro-
organisms up to the oropharynx. The process of
bacterial clearance from the peripheral airways
can last up to 6 h [15]. Over this period, the
presence of lactoferrin, lysozyme and secretory
leukoproteinase inhibitor, among other antimi-
crobial compounds from bronchial secretion,
hampers the growth of microorganisms [16]. The
respiratory airways will be kept sterile whenever
two factors, i.e., speed of drainage and bacterial
growth inhibitory capacity, are greater than the
total amount of microorganisms entering the
respiratory tract, taking into account their rate of
reproduction. Only those microorganisms (Myco-
plasma pneumoniae, C. pneumoniae and Bordetella
pertussis) that have speciﬁc mechanisms which
allow them to stick to the bronchial mucosa
epithelial layer, and therefore to avoid being
moved up to the oropharynx, will eventually
produce an infectious tracheobronchitis in healthy
people.
Reductions in the effectiveness of mucocilliary
drainage system, related to CB pulmonary patho-
logical changes, allow the bacterial colonisation of
bronchial lumen. Bacterial population density is
directly related to the degree of impairment of the
bronchial drainage system, which in turn corre-
lates well with the severity of airway obstruction.
In the initial stages of CB, among those patients
with FEV1 values > 60% of those predicted the
culture of bronchial secretions can be ‘apparently’
sterile (bacterial viable counts below 103
CFU ⁄mL). When the drainage system and ⁄ or
the obstruction worsens, the probability of being
colonised increases [17] and the bacterial density
also increases [18–20]. Any decline in the effect-
iveness of the drainage system, if lasting long
enough, will lead over the following days to a
new balance in which bronchial mucus tends to
harbour a greater degree of bacterial load. Micro-
organisms can be kept under very low, even
undetectable, numbers in bronchial mucus of
patients with stable CB, as conﬁrmed by the fact
that, after the sputum culture becomes negative
following appropriate antibiotic treatment, the
same bacterial phenotype will reappear when
clinical relapses of the disease develop [21,22].
The presence of bacteria on the surface of the
otherwise normally sterile mucosa triggers the
activity of leukocytes, the second defensive mech-
anism of innate immunity. Toll-like receptors
expressed in the epithelium of bronchial mucosa,
as well as in macrophages, will recognise speciﬁc
bacterial components [23]. The activation of nuc-
lear kB factor will start the production of cytok-
ines (interleukins, chemokynes) [24–26] growth
factors [27,28], intercellular adherence molecules
(selectines, ICAM) [29,30] and arachidonic acid
metabolites (B4 leukotriene) [31,32]. Direct conse-
quences include the development of an inﬂam-
matory response, with polymorphonuclear
leukocytes (PMN) adhering to pulmonary blood
vessel endothelium, and migrating into bronchial
lumen. The degree of inﬂammation, as well as the
number of PMN cells in the sputum of a CB
patient, is directly related to the bacterial density
in the bronchial secretion. It has also been noted
that a good relationship exists between the gross
appearance of the sputum (the greenish color of
purulent sputum is due to the presence of
leukocyte myeloperoxidase) and the PMN count
[33]. A grossly purulent sputum is likely to
harbour a high bacterial load in 90% of cases [34].
Antibacterial mechanisms of the neutrophils
include, among others, production of reactive
oxygen species (ROS), e.g., superoxide anion
hydroxyl radicals as well as hydrogen peroxide
[35,36], several serine proteases (elastase, prote-
inase 3, cathepsin G), matrix metalloproteinases
and cystein proteinases (cathepsines K, L and S).
The protease activity is rapidly neutralised by
speciﬁc inhibitors, e.g., alpha-1-antitrypsine, al-
pha-1-macroglobulin, elﬁn, secretory leukopro-
tease inhibitor,1 for tissue inhibitors of matrix
metalloproteinases (TIMPs) proteinases and cist-
atines. ROS can inactivate antiproteases. Free
proteases and2 ROS effects include the enhance-
ment of the inﬂammatory response, mucus pro-
duction [37–39] and the likelihood of lung
damage [40,41] with the ensuing worsening of
the airway obstruction (FEV1 reduction) [42–45],
ﬁnally leading to emphysema in animal models
[46,47] and very probably also in humans [48].
If the bacterial density is low, leukocyte counts
will also be low (giving a mucoid appearance to
the sputum), and several antiproteases can easily
neutralise the total amount of proteases produced
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by leukocytes. On the other hand, when the
bacterial counts are high, the purulent appearance
of the sputum is related to the higher concentra-
tion of proteases, which can then make ineffective
the antiprotease neutralising activity. The ﬁnal
result is likely to be worsening of the respiratory
tract obstruction, together with an impairment of
the mucocilliary drainage system, which in turn
maintains (or even increases) the growth of
bacteria. In summary, from a given threshold of
bacterial load in the bronchial secretion, the
degree of inﬂammatory response may enter a
vicious cycle (VC) which can sustain the process
[49]. Fig. 1 summarises these events.
Some data from patients with CB indicate that
the severity of the inﬂammatory response may
change as a function of the particular bacteria that
prevail in the bronchial mucus. Pseudomonas
aeruginosa produces a higher degree of inﬂamma-
tion than that produced by Haemophilus inﬂuenzae,
which in turn is higher than that due to Moraxella
catarrhalis or Haemophilus parainﬂuenzae [50,51].
Overall, the critical density of bacteria in bron-
chial mucus that leads to the VC lies around ‡ 106
CFU ⁄mL. Chronic production of purulent spu-
tum has been linked with an impairment of FEV1
[52], as well as with a higher risk of severe chronic
obstructive pulmonary disease (COPD) exacerba-
tions requiring hospitalisation [53,54]. Acute ex-
acerbations of CB are associated with the presence
of higher bacterial loads in the bronchial mucus
[19].
The clinical evolution of patients with CB is
characterised by the regular appearance of wor-
sening episodes of bronchial inﬂammation, due to
bacterial or viral infection in more than 60% of
cases [55,56]. The remaining episodes are due to
environmental factors (air pollution, dust, tem-
perature), lack of compliance with baseline treat-
ment or development of cardiac disrythmias,
among other infrequently encountered causes.
Viral infection is mainly due to rhinovirus [11,12
57] followed by coronavirus, respiratory syncitial
virus (RSV), inﬂuenza and parainﬂuenza virus
and adenovirus [58]. Recently, it has been dem-
onstrated that human metapneumovirus can play
a role in acute exacerbations of CB in up to a 4%
of cases [59]. Bacterial infection can be due to the
acquisition of a new H. inﬂuenzae strain [60–63] or,
less frequently, of a M. catarrhalis [64] strain, very
probably showing higher virulence when com-
pared with those strains that have been present
before in bronchial mucus [65]. Surface antigenic
protein genes of H. inﬂuenzae can mutate, allow-
ing the microorganisms to escape from immune
response [66,67], a property that perhaps could
explain some of the exacerbations. Several studies
[68–70] demonstrate serological evidence for
acute C. pneumoniae infection in up to a 5% of
CB exacerbations, an observation that was not
conﬁrmed by other authors [71].
Independently of the underlying cause, all
acute exacerbations of CB carry a risk of further
impairment of the mucocilliary drainage system
and of an increase in bacterial population density,
which in turn can trigger a greater inﬂammatory
response. Even when the initial trigger of the
acute exacerbation episode is not a bacterial
infection, there is an enhanced risk that, over the
next few days, bacteria will participate actively in
the process and determine its ﬁnal evolution
when the density threshold level for generating
the VC is reached. The likelihood of this series of
events depends on two main factors: the severity
and duration of the triggering cause and the
baseline situation of the CB patient. The greater
the bacterial charge at the baseline, the greater the
risk that any given phenomenon, independently
of its aetiology, will contribute to the bronchial
inﬂammation and lead to exacerbation due to an
even higher bacterial load (Fig. 2). Higher bacter-
ial loads under stable clinical conditions are often
seen among CB patients with a history of repeated
acute exacerbations [72] and ⁄ or moderate to
severe degrees of bronchial obstruction. The rate
of acute exacerbation is higher in patients at more
advanced stages of CB as measured by the degreeFig. 1. Development of the ‘Vicious Cycle’.
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of bronchial obstruction [73–75]. In a signiﬁcant
proportion of patients with acute exacerbation of
CB, the recovery is incomplete [76].
Bacterial species often found in the cultures of
bronchial secretion from CB patients, if sputum
samples are taken either during clinically stable
phases or during acute exacerbations, are (in
decreasing order), non-typable H. inﬂuenzae,
Streptococcus pneumoniae and M. catarrhalis [77].
In those patients with severe airﬂow impair-
ment (FEV1 < 40%), enteric Gram-negative
bacilli (enteric GNB) (Escherichia coli, Klebsiella,
Enterobacter) [78,79], as well as nonfermentative
GNB, mostly P. aeruginosa [80,81], can also be
isolated from bronchial secretions. Other bacteria
found less frequently include Staphylococcus
aureus and H. parainﬂuenzae. The presence of
GNB is due, to a great extent, to the higher
rate of antibiotic usage as treatment for acute
exacerbations among patients with moderate or
severe CB. Risk factors for pharyngeal coloni-
sation by GNB, e.g., advanced age and severe
underlying conditions (diabetes mellitus, chronic
renal failure, cirrhosis of the liver, cancer or
any other chronic debilitating disease) are also
risk factors for pharyngeal colonisation among
patients with CB.
Up to 20% of bronchial secretion samples from
CB patients will give a growth of polymicrobial
ﬂora. Often different H. inﬂuenzae strains coexist
in the same patient, even with differences in their
antibiotic susceptibility [82]. The presence of
pneumococci reduces the likelihood of colonisa-
tion or infection by H. inﬂuenzae [83]. The associ-
ation of H. inﬂuenzae with pneumococci is found
less frequently than expected, taking into account
the high frequency of their independent isolation
as a single pathogen.
DIRECTIONS FOR ANTIBIOTIC USE
IN ACUTE EXACERBATIONS OF CB
Following the evidence presented, the clinical
decision for or against using antibiotic treatment
in patients with acute exacerbation of CB must not
rely on ﬁnding a bacterial infection as the primary
cause of the exacerbation, a situation that in turn
is often difﬁcult to identify [84], but rather on the
acknowledgment of those situations in which
bacterial presence is a likely factor contributing
Fig. 2. Sequence of events leading to the start of the VC in patients with CB: A patient with CB start from point A, where the
bacterial load (left axis), and therefore the degree of purulent sputum (right axis) is low, as represented by the A¢ point, due
to a mild impairment of the mucocilliary drainage system. Once a cause for the acute exacerbation is present, the drainage
system is hampered, and patient’s status can move to B point, which corresponds to a B¢ level of bacterial load and purulent
sputum. If the B¢ point is close to or above the threshold level (> 106 cfu ⁄ml bacterial density), the Vicious Cycle can start
(see text). Adequate antibiotic treatment can reduce the degree of bacterial load, moving the patient down to point A¢.
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to the exacerbation, irrespectively of the initial
cause triggering the current episode.
The beneﬁts of an antibiotic treatment for acute
exacerbations of CB are a matter of debate. Well
known, published studies, where antibiotic was
compared to placebo, did not show statistically
signiﬁcant differences [85–88]. Reasons that could
explain these results include a low number of
patients in the studies, lack of stratiﬁcation of
patients according to severity scores of the acute
exacerbation, as well as the selection of antibiotics
or the antibiotic dosage, that may not be deemed
optimal, according to current knowledge of phar-
macodynamics.
The penetration of b-lactam antibiotics into the
bronchial secretion is due to a passive diffusion of
their free fraction (unbound to proteins). In the
best-case scenario, b-lactam antibiotic levels in
bronchial secretion will be c. 20% of their maxi-
mum plasma peak level. Antibiotics such as
cephaclor, cefuroxime or erythromycin, when
administered orally at the usually recommended
doses, will not last long enough in bronchial
mucus at levels above the MIC90 for H. inﬂuenzae
to develop their optimal antibacterial efﬁcacy.
A meta-analysis including nine randomised,
placebo-controlled, clinical trials, conducted be-
tween 1957 and 1992, showed a slight beneﬁt
favouring antibiotic against placebo when clinical
efﬁcacy and peak-ﬂow improvement were con-
sidered as end-points [89]. The study conducted
by Anthonisen et al. [90], in which patients were
stratiﬁed according to the severity of the acute
exacerbation, showed that beneﬁts of antibiotic
treatment (measured by the clinical improvement
as well as by the FEV1 values speed of improve-
ment) were particularly signiﬁcant when the
acute exacerbation episode was characterised by
the presence of dyspnoea, increased volume of
sputum and purulent appearance of the sputum.
Beneﬁt was lower, albeit still signiﬁcant, when
only two of these three criteria were met. Similar
results were obtained in another study where
patients were also classiﬁed into three groups
according to the severity of their bronchial
obstruction, measured by the FEV1 values.
Although antibiotic treatment efﬁcacy was better
than placebo in all groups, beneﬁts were higher in
the group of patients with a higher degree of
functional impairment [91].
Very important and valuable data regarding
antibiotic treatment of patients with acute exac-
erbations of CB were provided by a double blind,
randomised clinical trial, in which oﬂoxacin was
compared with placebo [92]. The study included
patients with a severe acute exacerbations of CB,
requiring mechanical ventilation. Patients in the
oﬂoxacin group less often needed other antibiotic
treatment. The total duration of mechanical ven-
tilation, length of hospital stay, as well as mortal-
ity rate were signiﬁcantly lower in the oﬂoxacin
than in the placebo group.
The use of antibiotics in patients with acute
exacerbations of CB can be decided following an
assessment of the clinical presentation of the
acute episode and of the baseline status of the
patient. This procedure allows the identiﬁcation
of two main groups of CB patients likely to
beneﬁt from antibiotic treatment: (1) patients
with severe acute exacerbations, who require
hospital admission, or patients with purulent
sputum production (a very good marker of the
presence of high bacterial counts); and (2)
patients with any degree of severity of the acute
exacerbation, but with advanced-stage CB, as
determined by severe airﬂow obstruction
(FEV1 < 40%), a prior history of three or more
acute exacerbations during the last year, or a
prior episode of severe acute exacerbation that
had required hospital admission.
The study conducted by Anthonisen et al. [90]
suggests that episodes of acute exacerbation of
CB in which at least two out of the following
three criteria were present (the so called Type II
exacerbations), will beneﬁt from antibiotic treat-
ment. The criteria include increase in shortness
of breath, increase in sputum volume and pro-
duction of purulent sputum. The relative weight
of the presence of purulent sputum is likely to be
higher than the presence of the other two
criteria, and probably justiﬁes, in itself, the use
of antibiotics. Patients with acute exacerbations
clinically characterised only by increased dys-
pnoea or increased volume of sputum produc-
tion have not been analysed independently.
Nevertheless, a recent study showed that pa-
tients with acute exacerbations of CB who
started the antibiotic treatment earlier had a
signiﬁcantly faster recovery rate, and also that
those patients who commonly do not consult a
primary physician when an acute exacerbation
appears had a higher likelihood of being admit-
ted to the hospital because of a more severe
episode [93].
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ADVANTAGES OF
FLUOROQUINOLONE USE AS
ANTIBIOTIC TREATMENT IN
PATIENTS WITH ACUTE
EXACERBATIONS OF CHRONIC
BRONCHITIS : CLINICAL
EXPERIENCE
The ﬂuoroquinolone (FQ) class of antibiotics
offers several advantages of special interest for
clinicians when used as empirical treatment for
respiratory tract infections. Their bactericidal
effect is rapid and dependent on the concentra-
tion achieved at the primary site of infection. Both
properties give a basis for the use of short-term
(5 days) treatment in patients with acute exacer-
bations of CB. The extended half-lives of most FQ
allow their use in a single daily dose.
The antimicrobial spectrum of activity of the
so-called third generation FQ (levoﬂoxacin,
gatiﬂoxacin and gemiﬂoxacin) or the fourth gen-
eration FQ (moxiﬂoxacin, garenoxacin) include
the most important microorganisms involved in
acute exacerbations of CB, e.g., H. inﬂuenzae,
M. catarrhalis and S. pneumoniae, together with
other microorganisms also identiﬁed occasionally,
e.g., C. pneumoniae andM. pneumoniae. In addition,
FQ are active against a high percentage of Entero-
bacteriaceae, and ciproﬂoxacin aswell as levoﬂoxa-
cin is active against a high number of P. aeruginosa
strains. Although the activity of levoﬂoxacin
against P. aeruginosa is lower than that of ciproﬂ-
oxacin, the in-vivo efﬁcacy of both quinolones is
similar, because the pharmacokinetic properties
of levoﬂoxacin are more favourable and allow this
antibiotic to achieve an area under the concentra-
tion-time curve over 24 h in steady state divided
by the MIC (AUC ⁄MIC) ratio equivalent to that of
ciproﬂoxacin [94]. The antibacterial spectrum of
activity of FQ acquires paramount importance
whenever there is a high antibiotic resistance rate,
as recorded in several areas of the world, where
H. inﬂuenzae and notably M. catarrhalis strains
are b-lactamase producers in 30% and 90% of
cases, respectively, and also where S. pneumoniae
strains show macrolide and penicillin-resistance
in nearly 30% of cases [95,96].
The diffusion of FQ antibiotics to lung tissue is
sufﬁcient. Levels achieved are higher than plasma
levels both in alveolar ﬂuid and inside alveolar
macrophages and, to a lesser extent, in bronchial
mucosa [97–100]. Second-generation FQ levels in
bronchial secretion reach values of 80– 200% of
plasma levels [101,102]. There are no data avail-
able for third and fourth generation FQ. The
pharmacodynamic parameter that best predicts
the clinical efﬁcacy of a FQ is the AUC ⁄MIC. The
complete elimination of S. pneumoniae is achieved
with AUC ⁄MIC values above 30 [103,104]. When
the infection is due to P. aeruginosa or enteric
GNB, AUC ⁄MIC values above 125 are needed
[105], which in turn requires the use of ciproﬂ-
oxacin at doses of 750 mg every 12 h or levoﬂ-
oxacin at doses of 500 mg every 12 h. The optimal
AUC ⁄MIC values for H. inﬂuenzae and M. catarrh-
alis are unknown, but are probably very close to
the values registered for pneumococci.
The potential existence of high bacterial loads
in acute exacerbations of CB is an important risk
factor for selection of resistant mutants. Mutations
occur spontaneously at the region that genetically
determines quinolone resistance (QRDR) of parC
and ⁄ or gyrA. A single mutation usually produces
a slight increase of the MIC and, depending on
the intrinsic FQ activity, the antibiotic could still
be effective. However, if a second mutation
appears, this will certainly lead to bacterial
cross-resistance against all FQ [106].
When an antibiotic susceptibility test is per-
formed, minor changes in resistance level must be
identiﬁed because they might point to the exist-
ence of a ﬁrst step mutation. Then, the use of FQ
should be avoided in order to prevent the selec-
tion of strains that developed a second step
mutation, which implies cross-resistance. For the
same reason, it is prudent to avoid long duration
FQ treatments in patients with CB, as well as to
avoid the use of FQ in patients with CB who have
been treated recently with FQ. The H. inﬂuenzae
and S. pneumoniae bacterial populations present in
bronchial secretions of a CB patient are often
heterogeneous. Clones with different antibiotic
susceptibility can easily coexist [82]. The FQ
resistant clone, perhaps arising from a prior FQ
treatment, could remain hidden by the vast
sensitive population, but it can be rapidly selected
and will prevail after a few days when a new FQ
antibiotic treatment course has started.
Since the beginning of the widespread use of
FQ antibiotics as treatment for respiratory tract
infection, several isolated cases [107,108], together
with small outbreaks [109], of FQ-resistant
S. pneumoniae respiratory tract infections have
been reported, notably in CB patients previously
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treated with FQ [110]. Most of the resistant
isolates had no relationship and clone dissemin-
ation is sparse to date [106].
Epidemiological studies conducted recently in
the United States [111–113], Canada [114] and
several European Union countries [115–117],
showed that the resistance rate of pneumococci
to FQ is still below the 1% level. Rare cases of FQ-
resistant H. inﬂuenzae [118] have been reported,
but both H. inﬂuenzae and M. catarrhalis remain
uniformly sensitive to FQ [119].
3 Table 1 includes the results of double blind,
randomised studies in which ciproﬂoxacin [120–
122], grepaﬂoxacin [123], levoﬂoxacin [124,125],
gemiﬂoxacin [126,127], gatiﬂoxacin [128,129]
and moxiﬂoxacin [130–133] are compared with
different macrolide antibiotics (azythromycin,
clarithromycin) or b-lactam antibiotics (amoxy-
clin-clavulanate, cefuroxime axetil) as treatment
for acute exacerbations of CB. All FQ except
ciproﬂoxacin have been used in 5-day treatment
courses against 7–10 day treatment courses for
the comparator antibiotics. Most studies include
CB patients with type I or type II acute exacer-
bations, as determined by Anthonisen’s study
criteria [90]. The clinical response, assessed at days
7–21 after treatment was deemed to be favourable
in 80–90% of cases. None of the studies showed
statistically signiﬁcant differences between treat-
ment arms. Bacterial elimination rates ranged
from 60 to 98%. In four of the 14 studies, the
sputum culture become negative in a signiﬁcantly
higher percentage of patients treated with a FQ
when compared with any other antibiotic used
[120,121,130,133]. Several studies conducted by
Chodosh [120] and Wilson [127], where the time
interval from the end of antibiotic treatment to the
next acute exacerbation episode was analysed,
demonstrate that the interval free of disease was
signiﬁcantly longer in the group of patients
treated with FQ. Besides the advantages evident
from these results, which include a better quality
Table 1. Double blind, randomized clinical trials, where FQ are compared against other antibiotics for the treatment of
patients with acute exacerbations of chronic bronchitis
Author ⁄ year Antibiotics
Dose
(mg ⁄h) Days
total number of
patients assessed
mean age
(years)
type of
exacerbation§
% with favorable
evolution (at 7–21 days)
bacteriologic eradication
cases ⁄ total (%)
Chodosh121 1998 Ciproﬂoxacin 500 ⁄ 12 14 99 61 I-II-III 90 86 ⁄ 95 (91) **
Clarithromycin 500 ⁄ 12 14 91 62 82 67 ⁄ 87 (77)
Chodosh122 1998 Ciproﬂoxacin 500 ⁄ 12 14 103 57 nd 93 89 ⁄ 93 (96) **
Cefuroxime 500 ⁄ 12 14 105 58 90 80 ⁄ 97 (82)
Grassi123 2002 Ciproﬂoxacin 500 ⁄ 12 10 110 65 II 85# 46 ⁄ 50 (92)
Pruliﬂoﬂoxacin 600 ⁄ 12 10 112 67 85 47 ⁄ 53 (89)
Langan124 1999 Grepaﬂoxacin 400 ⁄ 24 5 156 57 II 72 58 ⁄ 89 (65)
Grepaﬂoxacin 400 ⁄ 24 10 157 56 81 58 ⁄ 86 (67)
Clarithromycin 250 ⁄ 12 10 160 57 73 62 ⁄ 104 (60)
Masterton125 2001 Levoﬂoxacin 500 ⁄ 24 5 238 61 II 83 92 ⁄ 112 (82))
Levoﬂoxacin 500 ⁄ 24 7 244 59 85 84 ⁄ 101 (83
Amsden126 2003 Azythromycin 500-250 ⁄ 24 5 108 58 I-II 82 22 ⁄ 23 (96)
Levoﬂoxacin 500 ⁄ 24 7 104 59 I-II 86 17 ⁄ 20 (85)
Wilson127 2002 Gemiﬂoxacin 320 ⁄ 24 5 351 59 I 85 39 ⁄ 45 (87)
Clarithromycin 500 ⁄ 12 7 358 58 85 38 ⁄ 52 (73)
Sethi128 2004 Gemiﬂoxacin 320 ⁄ 24 5 170 62 I-II 88 (78)
Levoﬂoxacin 500 ⁄ 24 7 164 63 85 (86)
Gotfried129 2001 Gatiﬂoxacin 400 ⁄ 24 5 174 48 I-II 89 85 ⁄ 87 (98)
Gatiﬂoxacin 400 ⁄ 24 7 175 49 88 75 ⁄ 80 (94)
Clarithromycin 500 ⁄ 12 10 178 48 89 87 ⁄ 89 (98)
Soler130 2003 Gatiﬂoxacin 200 ⁄ 24 5 138 62 II 82 55 ⁄ 65 (86)
Gatiﬂoxacin 400 ⁄ 24 5 136 60 81 47 ⁄ 61 (77)
Amoxy-Clav. 500 ⁄ 8 10 126 62 82 51 ⁄ 67 (76)
Wilson131 1999 Moxiﬂoxacin 400 ⁄ 12 5 322 60 I-II 89 89 ⁄ 115 (77) **
Clarithromycin 500 ⁄ 12 7 327 60 88 71 ⁄ 114 (62)
Chodosh1322000 Moxiﬂoxacin 400 ⁄ 24 5 143 57 I-II 89 127 ⁄ 143 (89)
Moxiﬂoxacin 400 ⁄ 24 10 148 55 91 135 ⁄ 148 (91)
Clarithromycin 500 ⁄ 12 10 129 54 91 110 ⁄ 129 (85)
DeAbate133 2000 Moxiﬂoxacin 400 ⁄ 24 5 221 54 I-II 88 105 ⁄ 119 (88)
Azythromycin 500-250 5 243 54 88 102 ⁄ 118 (86)
Wilson134 2004 Moxiﬂoxacin 400 ⁄ 24 5 274 64 I 70 62 ⁄ 71 (91) **
Other Atb:
Amoxycillin 500 ⁄ 8
Clarithromycin 500 ⁄ 12 7 298 63 62 66 ⁄ 79 (81)
Cefuroxime 250 ⁄ 12
* assessment performed at days 2-7 after treatment
† assessment performed at day 2 after treatment
§ Type of exacerbation following Anthonisen’s classiﬁcation91
** p < 0.05
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of life for patients and lower cost of illness, a
reduction in the number of acute exacerbation
episodes implies a better preservation of antibi-
otic susceptibility due to its lesser usage, but also
a slowing in the rate of damage to the patient’s
respiratory function, which several other studies
linked to the annual number of acute exacerba-
tions [43].
Overall, data gathered from clinical effective-
ness studies using different FQ antibiotics suggest
that: (1) with intrinsic differences in activity,
different antibacterial spectrums of activity or
differences in their ability to penetrate in bron-
chial mucus can achieve similar clinical cure rates,
provided that they were able to reduce bacterial
population density below the threshold where the
inﬂammatory response tends to remain for a long
period or even worsen; and (2) the antibiotic that
achieves a greater reduction in bacterial load after
an acute exacerbation is able to defer longer the
next exacerbation episode. This could be ex-
plained by the fact that not only must the
following exacerbation episode start from lower
bacterial load counts, but more probably by the
improvement of inﬂammation related to a lower
bacterial load, because patients with persistent
colonisation show greater degrees of inﬂamma-
tion throughout their periods of clinical stability
[134].
Among the possible secondary or untoward
effects of FQ use, which can be particularly
relevant when they are prescribed for patients
with CB are: (1) development of tendon injuries;
(2) possible prolonged QT interval; and (3) inter-
actions with other drugs. Nearly 1% of patients
under FQ treatment will develop arthralgia and,
very infrequently, Achilles’ tendon injury, inclu-
ding a risk of tendon rupture. This untoward
effect is more likely to develop in patients with
chronic renal failure and ⁄ or patients treated with
steroid drugs [135]. The median duration of FQ
treatment before the onset of tendon injury was
8 days [135]. The prolonged QT interval was the
main factor for the market withdrawal of sparﬂ-
oxacin and grepaﬂoxacin. In healthy volunteers, a
1000 mg dose of levoﬂoxacin and a 1500 mg dose
of ciproﬂoxacin induce a 4 ms prolongation of the
QT interval. In the same study, a dose of 800 mg
of moxiﬂoxacin resulted in a 16 ms QT prolonga-
tion [136]. The risk of cardiac dysrhythmias
(torsades de pointes) is very low, but could be
increased if the patient has hypokaliemia, has a
major cardiac disease or is taking several antiar-
rhythmic drugs (amiodarone, quinidine, procain-
amide, sotalol), tricyclic antidepressants or other
antipsychotic drug treatment, which also lead to
QT prolongation. Hypotension has been des-
cribed with the use of garenoxacin.
Among possible drug–drug interactions, there is
a low probability of the development of a nonsol-
uble compound whenever FQ are administered
together with cations (calcium, iron, zinc, alumi-
num). For this reason, mineral dietary supple-
ments, antacid compounds and sucralfate can
signiﬁcantly reduce FQ absorption if the antibiotic
is not taken at least 4 h before or 2 h after.
Ciproﬂoxacin can increase the plasma levels of
theophylline because of its inhibition of P-450
cytochrome. The effect of levoﬂoxacin, gatiﬂoxacin
and moxiﬂoxacin on theophylline metabolism is
minimal. Gatiﬂoxacin can interact with oral hypo-
glycemic agents, and induce hypoglycemia [137].
Treatment of CB acute exacerbations with FQ
antibiotics achieves clinical cure rates at least
similar to those of other antibiotic groups
(b-lactams, macrolides). FQ have the additional
advantage that a single daily oral dose, used over
a 5-day treatment course, is usually enough. A
greater efﬁcacy of FQ antibiotics in reducing
bacterial load, as well as the likely implications
of this effect on the duration of the interval free of
exacerbations, together with a slowing of the rate
of functional impairment, justify the considera-
tion of FQ as the ﬁrst-choice antibiotic treatment,
notably in those patients with moderate to severe
CB (FEV1 < 60%), age above 65 years or comor-
bid conditions (diabetes, cardiac disease, cirrhosis
of the liver, chronic renal failure). In patients with
mild CB (FEV1 ‡ 60%), aged below 65 years and
without comorbidity, FQ antibiotics are an option
for treatment as are amoxycillin-clavulanate or
telithromycin (used in those areas with high
resistance rates to macrolides among pneumococ-
ci). It is prudent to state clearly this difference, in
order to avoid a widespread use of FQ for all CB
acute exacerbation episodes that warrant treat-
ment, and to reduce the likelihood of resistance
development. CB patients with a prior history of
more than four acute exacerbation episodes
requiring antibiotic treatment over a 1-year per-
iod have a high risk for P. aeruginosa coloni-
sation. In those cases, it is recommended that a
sputum sample for culture and antibiotic suscep-
tibility testing always be obtained, because the
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P. aeruginosa resistance rate to FQ in some areas is
high [138]. Until the results become available, if
oral antibiotic treatment is considered, ciproﬂoxa-
cin or levoﬂoxacin should be used.
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